IMPORTANT UPDATES

To submit a grant request you must first be registered in the Request Management System (RMS).

Using Google Chrome or Firefox, go here to register:  https://webportalapp.com/sp/login/teva-registration.

Once your registration is approved, you will receive an email from the RMS with the submission link (https://webportalapp.com/sp/login/teva-grantrequest) and you will be able to submit a request. You must use this link for submissions.

 

For refund checks, please submit to: Teva Pharmaceuticals, Attention: Medical Education Department, 400 Interpace Parkway, Parsippany, NJ 07054

For any inquiries, please email: tevarequestmanagement@tevapharm.com and include the grant number if applicable.

 

important

Education Objectives: Huntington's Disease

Huntington’s Disease - HCP

  • Support education to improve HCP knowledge and competence in diagnosing Huntington’s Disease (HD), including understanding genetic factors, disease state pathophysiology, and the triad of symptoms that may impact quality of life
  • Support education to improve HCP understanding of the disease burden and improve competence in understanding the clinical profile of treatment options for Huntington’s Disease
  • Support education in managing Huntington’s Disease-related chorea to help understand HCP needs, patient unmet needs and the importance of early and continuous treatment as well as the importance of adherence and persistence
  • Support education to increase competence and confidence in managing Huntington’s Disease including using a multidisciplinary approach, identifying the appropriate treatment, understanding the importance of long-term treatment and understanding barriers to treatment  

HD Audience Groups: Neurologists, Psychiatrists, Nurses, NursePractitioners,  Physician Assistants, Social Workers, Physical Therapists/Occupational Therapists/Speech Language Pathologists, Primary Care Physicians, Pharmacists, medical trainees/medical students/interns/residents/fellows, Managed Care HCPs

Education Objectives: Tardive Dyskinesia

Tardive Dyskinesia - HCP

  • Support education to improve HCP knowledge and competence in understanding, recognizing and diagnosing Tardive Dyskinesia, including risk factors associated with TD
  • Support education to improve HCP knowledge of current treatment options for Tardive Dyskinesia, the importance of early and continuous treatment and the impact of untreated TD
  • Support education to increase HCP confidence and competence in assessing and managing Tardive Dyskinesia throughout the patient journey
  • Support education to increase HCP confidence and competence in VMAT2 inhibitors by addressing barriers to long-term treatment success and increasing understanding of appropriate dosing for titration and maintenance

TD Audience Groups:  Psychiatrists, Nurse Practitioners, Neurologists, Nurses, Physician Assistants, Pharmacists, Long Term Care HCPs, Social Workers, Physical Therapists/Occupational Therapists/Speech Language Pathologists, medical trainees/medical students/interns/residents/fellows, Managed Care HCPs

Education Objectives: Schizophrenia

Schizophrenia – HCP

  • Support education to improve understanding of the disease state of schizophrenia and its burden on patients and caregivers
  • Support education to increase competence in treating schizophrenia, in recognizing non-adherence and in preventing relapse 
  • Support education to increase the understanding of the impact of suboptimal efficacy and subsequent treatment considerations
  • Support education on the pharmacological components (MOA, receptor binding profiles, etc.) and the clinical data profile of current and emerging antipsychotics
  • Support education to increase the understanding of how to navigate barriers to utilizing Long Acting Injectables (LAIs) – including education on clinical considerations for switching treatments
  • Support education to increase awareness on the importance of broadening the use of LAIs as reflected in the literature and recent guidelines

Schizophrenia Audience Groups:  Psychiatrists, NPs, PAs, Nurses, Pharmacists, medical trainees/medical students/interns/residents/fellows in both community and in-patient settings, Managed Care HCPs

Education Objectives: Bipolar Disorder

Bipolar Disorder (BPD-1) – HCP

  • Support education to improve understanding of the disease state of BPD-1 including accurate diagnosis and its burden
  • Support education to increase competence in treating BPD-1, in recognizing non-adherence, and in preventing relapse
  • Support education to increase the understanding of the use of antipsychotics in treating BPD-1 
  • Support education on the Model-Informed Drug Development (MIDD) FDA program and on pharmacological components (MOA, receptor binding profiles, etc.) of antipsychotics
  • Support education to increase the understanding of how to navigate barriers to utilizing Long Acting Injectables (LAIs) ​
  • Support education to increase awareness on the importance of broadening the use of LAIs as reflected in recent literature and guidelines

BPD-1 Audience Groups:  Psychiatrists, NPs, PAs, Nurses, Pharmacists, medical trainees/medical students/interns/residents/fellows in both community and in-patient settings, Managed Care HCPs

Education Objectives: Biosimilars

Biosimilars – HCP

  • Support education to increase HCP knowledge of biosimilars including understanding what they are, the terminology used, regulatory approval process, what their role is in healthcare, etc.
  • Support education to increase HCP confidence in using biosimilars, including their understanding about interchangeability and different concentrations
  • Support education to improve HCP understanding of the attributes of the current and emerging adalimumab biosimilars as treatment options  

Biosimilar Audience Groups:  Dermatologists, Gastroenterologists, Primary Care Physicians, Rheumatologists, Nurses, Nurse Practitioners, Physician Assistants, Pharmacists, Managed Care HCPs